Kuvatris Therapeutics, Inc.
Kuvatris Therapeutics, Inc. (PXMD): 2 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.6 months
D/E -1.42 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for Kuvatris Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$63K
Cash
$445K
Quarterly Burn
$632K
Runway
2.6 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Kuvatris Therapeutics, Inc.'s pipeline?
Kuvatris Therapeutics, Inc. (PXMD) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Kuvatris Therapeutics, Inc.'s lead drug candidate?
Kuvatris Therapeutics, Inc.'s most advanced tracked candidate is pax-101 (Phase 2) for Autism Spectrum Disorder (ASD).
What is Kuvatris Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Kuvatris Therapeutics, Inc. has approximately 2.6 months of cash runway.
What is Kuvatris Therapeutics, Inc.'s market capitalization?
Kuvatris Therapeutics, Inc.'s market capitalization is approximately $63K.
Who is the CEO of Kuvatris Therapeutics, Inc.?
Mr. Howard J. Weisman is the chief executive officer of Kuvatris Therapeutics, Inc. (PXMD).
Get the full picture on Kuvatris Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.